期刊
CANCER
卷 122, 期 18, 页码 2787-2798出版社
WILEY
DOI: 10.1002/cncr.30094
关键词
clinical trials; endometrial cancer; genomics; Lynch syndrome; molecular classification; obesity and lifestyle factors; DNA polymerase epsilon catalytic subunit (POLE) mutations; targeted therapy; The Cancer Genome Atlas (TCGA)
类别
资金
- Canadian Institute of Health Research
- Canadian Cancer Society
- British Columbia Cancer Foundation
Worldwide, the incidence of endometrial carcinoma (EC) is rapidly increasing, and the highest disease burden is reported in North America and Western Europe. Although the prognosis remains good for patients with are diagnosed with early stage EC, for those with recurrent or metastatic disease, the options are few, and the median overall survival is short. It is imperative to gain a greater understanding of all aspects of EC, limit its effect on scarce health care resources and, more importantly, prevent this cancer from significantly impacting future generations of women. An exciting new era of endometrial cancer research and clinical management has begun that incorporates biologically and clinically relevant genomic and clinicopathologic parameters. Continued collaborative research efforts and funding are essential if we are to advance our understanding of this disease and improve clinical outcomes. Cancer 2016. (c) 2016 American Cancer Society. Cancer 2016;122:2787-2798. (c) 2016 American Cancer Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据